M agnesium, the fourth most abundant cation in the organism and the second in intracellular enviro n m e n t , takes part in more than 300 enzymatic re a ctions (1). Because magnesium is a pre d o minantly intracellular ion, serum and plasma m e a s u rements may not be re p resentative of the total body content, and a significant ion depletion with normal serum levels may occur (2). Ery t h rocyte, mononuclear cell, and muscle have been used for determ i n ation of intracellular magnesium concentrations (3). Mononuclear cells are pro b a b l y the compartment that best correlates with muscular magnesium (4).
Hypomagnesemia has been shown to occur in 25-38% of patients with diabetes, especially in those without good metabolic c o n t rol (5-10). Magnesium modulates glucose transport through the membranes and is a cofactor in several enzymatic systems involving glucose oxidation (11). Its deficiency may increase insulin resistance or may be its result (12). It is an AT P a s e allosteric effector involved in inositol transp o rt and possibly contributes to the prevention or delay of the development of c h ronic complications (13). Some observations have suggested that c h ronic magnesium supplementation may be useful in the treatment of patients with diabetes, improving the glycemic contro l and preventing the development of chro n i c complications (14,15). However, studies d i v e rge as to the amount of the daily dose, the period of replacement, and the degre e of glycemic control of the patients under t reatment (16) (17) (18) (19) .
The aim of this study was to evaluate the e ffect of magnesium in increasing doses on the control of patients with type 2 diabetes.
RESEARCH DESIGN AND M E T H O D S

Patients
This study was perf o rmed on 128 patients with type 2 diabetes without good metabolic c o n t rol (HbA 1 c 8.0 %), treated by diet or diet plus oral hypoglycemic drugs, seen in the Diabetic Clinic of Bahia Federal University Hospital (Hospital Universitário Pro f e ssor Edgard Santos), Salvador-B a h i a -B r a z i l . The oral agents used were sulfonylureas (glybenclamide) in 106 patients and biguanides ( m e t f o rmin) in 3 patients. Two patients used a combination of glybenclamide and metf o rmin. Seventeen were treated by diet only. Exclusion criteria were reduction of re n a l function, expressed by creatinine clearance 70 ml m i n 1 1.73 m 2 ; age 70 years; use of diuretics; persistent diarrhea; and alcoholism. A control group of 57 blood donors was used in the study as re f e rence values for magnesium concentrations.
Study design
The study design was a clinical random-O B J E C T I V E -Hypomagnesemia occurs in 25-38% of patients with type 2 diabetes. Several studies have suggested an association between magnesium (Mg) depletion and insulin resistance and/or reduction of insulin secretion in these cases. Our purpose was to evaluate if Mg supplementation (as magnesium oxide [MgO] ) would improve metabolic control in patients with type 2 diabetes. R E S U LT S -Of the patients, 47.7% had low plasma Mg, and 31.1% had low intramononuclear Mg levels. Intracellular Mg in patients with diabetes was significantly lower than in the n o rmal population (62 blood donors; 1.4 ± 0.6 vs. 1.7 ± 0.6 µg/mg of total proteins). No correlation was found between plasma and intracellular Mg concentrations (r = 0.179; P = 0.15) or between Mg concentrations and glycemic control (r = 0.165; P = 0.12). Intracellular Mg levels were lower in patients with peripheral neuropathy than in those without (1.2 ± 0.5 vs. 1.5 ± 0.6 µg/mg). Similar findings were observed in patients with coro n a ry disease (1.0 ± 0.5 vs. 1.5 ± 0.6 µg/mg). In the placebo and in the 20.7 mmol Mg groups, neither a change in plasma and intracellular levels nor an improvement in glycemic control were observ e d . Replacement with 41.4 mmol Mg tended to increase plasma, cellular, and urine Mg and caused a significant fall (4.1 ± 0.8 to 3.8 ± 0.7 mmol/l) in fructosamine (normal, 1.87-2.87 mmol/l).
RESEARCH DESIGN AND METHODS
C O N C L U S I O N S -Mg
depletion is common in poorly controlled patients with type 2 diabetes, especially in those with neuropathy or coro n a ry disease. More prolonged use of Mg in doses that are higher than usual is needed to establish its routine or selective administration in patients with type 2 diabetes to improve control or prevent chronic complications. 
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ized double-blind placebo-controlled trial. The patients were initially subjected to a clinical and laboratory evaluation and then randomized to receive placebo (group 1) or magnesium oxide (20.7 or 41.4 mmol/day MgO, in three doses) (groups 2 and 3) for 30 days. After this period, patients were subjected to a subsequent evaluation when compliance to tre a t m e n t was assessed. All subjects gave their i n f o rmed consent, and the study was a p p roved by the ethics committee of our i n s t i t u t i o n .
Analytical procedures L a b o r a t o ry tests perf o rmed were determ inations of fasting blood glucose (glucose oxidase; re f e rence value [RV], 3.9-6.3 mmol/l), HbA 1 (ionic exchange resin; RV, 6.0-8.0%), and fructosamine (nitro t e t r azolium blue reduction; RV, 1.87-2.87 mmol/l) and determinations of magnesium in plasma (RV, 0.70-0.88 mmol/l), 24-h urine (RV, 50-150 mg/24 h), and mononuclear cells (RV, 1.07-1.31 µg/mg of pro t e i n ) by atomic absorption spectro p h o t o m e t ry.
Mononuclear cells separation was perf o rmed as follows. All reagents used for white cell isolation were washed with HCl and deionized water. Whole blood was collected in heparinized vacutainer tubes. Te n ml of whole blood was layered on 3 ml of Histopaque (Sigma; n 1077) and centrifuged at 400g for 30 min at room temp e r a t u re (20). The plasma was separated, and the mononuclear cells were aspirated by Pasteur' s pipettes, layered into another tube, washed three times with 0.9% NaCl, and frozen at 35°C until ready for assay. The magnesium content of cells was measu red after lysis by defrosting and measure d by atomic absorption spectro p h o t o m e t ry. Magnesium concentration in mononuclear cells was expressed as micrograms per milligram total protein. Cell protein was measu red using the method described by Lowry and modified by Rodrigues (21). The fin a l suspension consisted of a mean of 97.5% lymphocytes, 2.3% monocytes, and 0.15% n e u t ro p h i l s .
All the assays were completed in the Endocrine Division Laboratory of Bahia Federal University Hospital. The pro t e i n d e t e rmination in mononuclear cells was p e rf o rmed in the Department of Biochemi s t ry of Bahia Federal University.
Statistical analysis
Continuous quantitative data are expre s s e d as means ± SD. Two-tailed parametric tests w e re used for comparison of normally distributed variables. Nonparametric tests w e re used to compare variables when the assumption of normal distribution was not met. After pre l i m i n a ry analysis of variance for the comparison of mean values between the three groups, Student' s paired t test or Wilcoxon test was perf o rmed before and after treatment comparisons. For nonpaire d comparison, independent t test or MannWhitney test was used. For the categorical variables comparisons, 2 or Fisher' s exact test was used. To assess possible re l a t i o nships between continuous variables, Pears o n ' s correlation coefficient was used. A two-tailed P value 0.05 was considere d statistically signific a n t .
Data analysis was perf o rmed by means of the Statistical Package for the Social Sciences (SPSS), version 6.0.1.
R E S U LT S -
Basal characteristics of the studied groups are shown in Table 1 . As a re f e rence population for establishing normal magnesium levels in our area, 57 healthy blood donors were studied (36 men and 21 women) with ages vary i n g between 18 and 54 years (32 ± 8.6 years).
Of the 128 patients who started the s t u d y, 29 did not follow instructions corre c t l y. The data were analyzed according to their original groups, based on the intention to treat. Reasons for interruption of tre a tment were irregular use of oral hypoglycemic drugs in 4 patients, other medical p roblems in 9 patients, and irregular use of Mg or placebo in 16 patients. Of these, 6 f o rgot to use the drug and the remaining 10 discontinued treatment due to side eff e c t s . Of the group treated with 41.4 mmol MgO, only one patient interrupted treatment due to undesirable event. The most fre q u e n t side effect was diarrhea, in 12% of the gro u p that used 41.4 mmol MgO, but only the above-mentioned patient interrupted the t reatment for this reason. Abdominal pain and nausea were not reasons for discontinuation of Mg administration in this gro u p .
B e f o re magnesium replacement, 47.7% of patients had low plasma Mg levels, and 31.1% had low intramononuclear levels. Intracellular Mg in patients with diabetes was significantly lower than in norm a l individuals, but no statistically signific a n t d i ff e rences were found among plasma magnesium concentrations (Table 2) . No correlation was seen either between plasma and intracellular Mg concentrations (r = 0.179; P = 0.15) or between Mg levels and glycemic control, as expressed by HbA 1 concentration (r = 0.165; P = 0.12).
In the 29 patients with peripheral neuro p a t h y, intracellular Mg levels were lower than in those without it (1.2 ± 0.15 vs. 1.5 ± 0.6 µg/mg total protein; P 0.05). Similar observations was made in eight patients with coro n a ry disease (1.03 ± 0.48 vs. 1.47 ± 0.34 µg/mg total protein). No diff e re n c e s w e re observed in intracellular magnesium of patients with retinopathy (1.45 ± 0.46 vs. 1.45 ± 0.57 µg/mg; Fig. 1 ). (years) 7.3 ± 5.4 7.2 ± 4.9 7.1 ± 5.5 BMI (kg/m 2 )
25.5 ± 6.5 25.3 ± 8.0 25.5 ± 6.5
Data are means ± SD or n (%). Data are means ± SD. *P 0.05. Table 3 shows magnesium concentrations and glycemic control parameters b e f o re and after treatment. In the placebo and the 20.7 mmol MgO groups, neither a change in plasma and intracellular levels nor improvement in glycemic control was o b s e rved. An increase in ion urinary excretion in the patients who received MgO was o b s e rved (P 0.005). Replacement with 41.4 mmol MgO tended to incre a s e plasma, cellular, and urine MgO and caused a significant fall in fru c t o s a m i n e levels (4.1 ± 0.8 to 3.8 ± 0.7 mmol/l; P 0.05). No changes in fasting blood glucose or HbA 1 concentrations were observ e d .
The percentage of patients with i m p rovement of metabolic control during t reatment is shown in Fig. 2 . Of patients who used the higher dose of magnesium, 73% showed a decrease in fru c t o s a m i n e . This finding was significant when comp a red with data from the placebo gro u p .
Weight, as expressed by BMI, did not change significantly in our patients during the study (BMI: group 1, 25.5 ± 6.5 → 2 5 . 4 ± 6.0; group 2, 25.3 ± 8.0 → 25.2 ± 7 . 8 ; g roup 3, 25.5 ± 6.1 → 25.4 ± 6.2 kg/m 2 ) .
C O N C L U S I O N S -
In this study, magnesium deficiency in plasma and mononuclear cells occurred with a frequency higher than that found by other re s e a rc h e r s (5, (7) (8) (9) (10) . This is probably due to the fact that the patients under study were not in good metabolic contro l .
Levels of intracellular magnesium were lower than those in the re f e rence population. Blood donors, although younger than the population studied, were used as a re fe rence group. This is justified by the fact that Reinhart et al. (2), after measuring concentrations of plasma and mononuclear magnesium in 88 volunteers, observed no d i ff e rences between sex and age.
T h e re was no correlation between intracellular and serum magnesium levels. This finding confirms what has been e n c o u n t e red by other authors (2,22,23). Quamme and Dirks (24) analyzed 13 studies where magnesium determination in mononuclear cells was used, and 10 of these considered the method useful, correlating well with muscular cells (where 27% of the total body magnesium was found) .
Some authors point to a negative correlation between magnesium levels and glycemic control (5, 10, 25) , but other re s e a rchers do not confirm this (26). Neither does our current study observe a correlation between levels of magnesium in plasma or in mononuclear cells with glycemic control parameters.
The link between magnesium deficiency and chronic diabetes complications is re p o rted by several re s e a rchers, pro b a b l y as a result of its positive action in inositol t r a n s p o rt (through ATPase activation) (13) or of its action reducing blood platelet a g g regation (27) . In this study, we observ e d that intramononuclear magnesium levels w e re low in patients with peripheral neuro p a t h y. To our knowledge, these data have not yet been re p o rt e d .
Despite the small number of patients with coro n a ry disease, the intramononuclear magnesium was significantly lower in this group of individuals. Some re s e a rchers suggest an association between hypomagnesemia and coro n a ry disease (28, 29) . Nadler et al. (27) point out that hypomagnesemia may double the risk of developing coro n a ry disease in a diabetic patient because of the increase in platelet reactivity usual in this situation.
The dose of elementary magnesium used in various studies varies gre a t l y (15-125 mmol/day) (16-19). However, doses greater than 41.4 mmol are not usu- 
